Success for Alecensa as it meets primary endpoint in another patient group
Genentech will meet with the FDA and EMA after the successful Phase III study of Alecensa in early-stage ALK-positive NSCLC.
Clinical Trials Arena Excellence Awards
Enter the Excellence Awards today! This program offers multiple benefits, such as gaining visibility among the market, your employees, and prospective clients for your achievement. To learn more about benefits, entry details, and available marketing packages, download the Research Guide.
